The monoclonal antibody bamlanivimab is no longer recommended as monotherapy for the
treatment of COVID-19 in Colorado.
The prevalence of B.1.427/B.1.429 variants is now estimated to be greater than 20% of all
Colorado cases; mutations in these variants are expected to confer resistance to bamlanivimab.
https://drive.google.com/file/d/1AehPczjqZg-Zq_3nv-_2sKMK9Um1TiKj/view?usp=sharing
DS